Side-by-side research comparison of CJC-1295 and Ipamorelin across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. No direct head-to-head trials in our corpus — this comparison synthesizes indirect evidence across 19 CJC-1295 studies and 36 Ipamorelin studies.
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Drug class | ghrh analog | ghrh secretagogue, ghrelin mimetic |
| Studies in corpus | 19 | 36 |
| Highest evidence tier | rct | rct |
| Evidence tier mix | preclinical animal · 5 rct · 2 other · 4 in vitro · 1 | other · 6 preclinical animal · 16 in vitro · 3 rct · 2 review · 1 |
| Studies with explicit sample size | 1 | 3 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real CJC-1295 and Ipamorelin batches we've tested. Aggregate, public data — cross-reference against the studies below.
We tested 1100 CJC-1295 batches across 397 manufacturers, 97.8% avg purity.
We tested 2109 Ipamorelin batches across 690 manufacturers, 99.5% avg purity.
We hold deeper lab coverage on Ipamorelin (2109 batches tested). Ipamorelin edges ahead on average measured purity (97.8% vs 99.5%) — a narrow gap; weigh it against failed-batch and underdose counts above.
Looking for vendor-level purity, endotoxin, and HPLC data on CJC-1295 or Ipamorelin? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.